We are thrilled that the 2024 Scrip Awards recognized our pioneering work and innovation in drug discovery and development for patients. Congratulations to all the winners across categories! #ScripAwards

We’re pleased to share an update on our ongoing Phase 1/2 dose escalation clinical trial evaluating the safety & efficacy of CTX112™, a next-generation CD19 allogeneic CAR T cell therapy, in relapsed or refractory CD19-positive B-cell malignancies: bit.ly/4ivSCZB #ASH24

We’re proud to have presented our latest findings at #ASH24. Thank you to our team for their hard work, dedication, and collaboration in making this possible. It’s inspiring to share progress and innovation with the scientific community as we continue advancing our programs.

We are pleased to invite Briggs Morrison, M.D., to join our Board of Directors. His extensive experience in the pharmaceutical industry and expertise in clinical development will be invaluable as we continue advancing our platform and pipeline. Learn more: bit.ly/420Fhmf

We are pleased to share that we will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference. We hope you can join us for the presentation on Tuesday, January 14 at 2:15pm PT in San Francisco: bit.ly/3W6j6HO #CRISPRTX

We are excited to highlight our strategic priorities and outlook for 2025 as we enter our next phase of growth. Learn more here: bit.ly/40kAo5k #CRISPRTX

Today, we announced our fourth quarter and full year earnings results. Read more about our recent highlights and outlook: bit.ly/3QfdKGL

March 24th is Lipoprotein(a) Awareness Day, an initiative by the Family Heart Foundation. This day aims to raise awareness of elevated Lipoprotein(a), also known as Lp(a), as an under-recognized cause of premature heart disease and stroke. Learn more at: bit.ly/4aNKEaT #KnowLpa

#NationalCancerResearchMonth is an awareness campaign initiated and supported by the AACR. We are proud to recognize this initiative, which highlights the importance of innovative cancer research. Learn more here: bit.ly/4aqqyma

Today, we reported our first quarter earnings results and announced positive top-line data from our Phase 1 clinical trial of CTX310™ targeting ANGPTL3. Read more about our recent highlights and business update: bit.ly/3GG89rv #CRSP #CRISPRTX

Today is #WorldThalassemiaDay. #Thalassemia is a #blooddisorder where the body does not make enough hemoglobin, which carries oxygen to the cells in the body. Today, we raise awareness for this condition. Learn more about it here: bit.ly/4ghR0R2

May is #LupusAwarenessMonth and today is #WorldLupusDay. This month, the community comes together to raise awareness about #lupus and its impact on many facets of life. Learn more about this awareness month at Lupus Foundation of America's website: bit.ly/40SMNie

Today, we announced a collaboration with Sirius Tx to co-develop SRSD107, a next generation, long-acting Factor XI siRNA for the treatment of thromboembolic disorders. This will expand our cardiovascular portfolio and broaden our therapeutic toolkit. bit.ly/4kjPEaS

Meet Keturah, an individual living with #TCellLymphoma. From her long journey to diagnosis, to her role as an advocate for the T cell lymphoma community, Keturah's story continues to inspire us. Read her story here: bit.ly/4h5hXaO

On #WorldSickleCellDay, we #ShinetheLightonSickleCell and raise awareness about the impact of #SickleCellDisease. Learn more about #SCD here: bit.ly/3xpC9mW

Today, we announced updates across our in vivo cardiovascular programs, which include new data for CTX310 (targeting ANGPTL3) as well as continued progress on CTX320 (targeting the LPA gene) and CTX340 (targeting the AGT gene): bit.ly/3HYdACE

We're proud to be named on TIME's Most Influential Companies of 2025 list – a recognition for our work toward bringing genetic medicines to people suffering from serious diseases on a global scale. Congrats to all the #TIME100Companies! time.com/collections/ti…

Today, we announced our second quarter earnings results. Read more about our recent highlights and outlook: bit.ly/3HeOP5h #CRSP